AR and Alzheimer disease: Tau-5, which plays a key role in transactivation by the splice variants associated with CRPC, harbors the binding site of EPI-001 (ref. 23), a small-molecular inhibitor of the AR AD discovered by phenotypic screening24, a derivative of which is being investigated in clinical trials for CRPC (NCT04421222, NCT05075577).